Semler Scientific (SMLR) AI Stock Analysis

• Market Cap: $394.99M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): 7.5
• Beta (1Y): 1.73
• Revenue Growth: -25.28%
• EPS Growth: -172.20%
• Country: US
• Employees: 79
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -6.74
• Shares Outstanding: 11,151,572
• 10 Day Avg. Volume: 1,498,147
• 30 Day Avg. Volume: 1,321,303
• PEG Ratio: -0.92
• Price to Book (P/B): 3.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 14.51
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 4.45
• Enterprise Value/Ebitda: 3.92
• 1Y Price Target: $71.00
• Price Target Upside: 79.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: $40.00 ▲(1.16%Upside)

Semler Scientific's overall stock score is primarily impacted by its financial performance, which is currently weak due to declining revenues and profitability. The company's strategic focus on Bitcoin has been positively received, but the financial challenges and poor valuation metrics weigh heavily on the score. Technical indicators suggest potential for upward movement, but caution is advised given the stock's position relative to its long-term moving average.

Positive Factors

Cash Flow

The business is generating significant positive free cash flow now, and this is expected to continue.

Regulatory Approval

Semler is seeking to obtain a new 510(k) clearance from the FDA that would allow the Company to market a heart dysfunction product.

Treasury Strategy

The Company has added Bitcoin to its Treasury strategy, and it is clear management and the Board view Bitcoin as central to the future of Semler.

Negative Factors

Bitcoin Volatility

The inherent volatility of Bitcoin is viewed as a risk for investors.

Cryptocurrency Holdings

The Company had an unrealized gain of roughly $29M from BTC in the quarter and ended Q4 with roughly $9M of cash.

Regulatory Changes

Preliminary 4Q results again reflected some of the fallout from last year’s announcement of CMS’ decision to phase out risk payments for asymptomatic PAD testing over the next 3 years.

Semler Scientific Business Overview & Revenue Model

Company Description

Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.

How the Company Makes Money

Semler Scientific makes money primarily through the sale and licensing of its QuantaFlo product to healthcare providers, insurance companies, and other medical facilities. The company employs a licensing model where clients pay a recurring fee for the use of the QuantaFlo device and software, providing a steady stream of revenue. Additionally, Semler Scientific may generate income from partnerships with insurance companies or other healthcare organizations that integrate their diagnostic tools into broader health assessment programs. The company's focus on addressing chronic vascular conditions helps position its products as essential tools in preventative healthcare, further enhancing its revenue potential.

Semler Scientific Financial Statement Overview

Summary

Semler Scientific's financial performance shows mixed results. The income statement reveals declining revenue and profitability, with negative EBIT and EBITDA margins. The balance sheet remains stable with strong equity, but increased leverage due to rising debt poses risks. The cash flow statement indicates significant negative free cash flow due to high capital expenditures, reflecting challenges in cash management.

Income Statement

The income statement shows mixed performance. The company experienced a significant drop in revenue in the TTM period compared to the previous year, with a revenue decrease from $56.29M to $49.23M, indicating a negative revenue growth rate of approximately -12.79%. The gross profit margin remains high but has declined slightly, and both EBIT and EBITDA margins have turned negative in the TTM period, primarily due to operating losses, reflecting declining profitability. Overall, the income performance suggests challenges in maintaining revenue and profitability.

Balance Sheet

The balance sheet reveals a strong equity base with stockholders' equity at $161.68M in the TTM period, which is a positive sign of financial stability. However, the debt-to-equity ratio has increased significantly due to a rise in total debt to $96.09M, indicating higher leverage. The equity ratio remains solid, but the increased leverage poses potential risks if not managed effectively. Overall, the balance sheet is stable but indicates potential risk from increased debt levels.

Cash Flow

The cash flow statement indicates a concerning trend with negative free cash flow of -$172.79M in the TTM period, primarily due to substantial capital expenditures. The operating cash flow remains positive at $16.88M, but the negative free cash flow suggests that capital investments are not currently translating into financial returns. Additionally, the operating cash flow to net income ratio shows strain due to negative net income. The cash flow situation reflects challenges in cash management and strategic investments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.23M	56.29M	68.18M	56.69M	53.03M	38.60M
Gross Profit	44.77M	51.53M	61.20M	52.43M	46.91M	35.25M
EBITDA	-15.59M	21.51M	23.28M	17.79M	19.45M	15.96M
Net Income	-29.88M	40.90M	20.58M	14.32M	17.22M	14.01M
Balance Sheet
Total Assets	293.44M	239.83M	78.06M	62.69M	50.67M	34.64M
Cash, Cash Equivalents and Short-Term Investments	9.74M	14.92M	57.20M	43.09M	37.32M	22.08M
Total Debt	96.09M	70.00K	160.00K	245.00K	325.00K	332.00K
Total Liabilities	96.09M	9.08M	6.27M	7.02M	5.13M	4.85M
Stockholders Equity	161.68M	230.75M	71.80M	55.68M	45.55M	29.79M
Cash Flow
Free Cash Flow	-172.79M	24.36M	20.50M	15.30M	15.23M	14.36M
Operating Cash Flow	16.88M	24.41M	21.33M	17.46M	16.06M	15.42M
Investing Cash Flow	-277.21M	-189.98M	18.40M	-26.84M	-825.00K	-1.31M
Financing Cash Flow	207.32M	117.19M	-5.41M	-4.94M	13.00K	230.00K

Semler Scientific Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 39.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SMLR, the sentiment is Positive. The current price of 39.54 is above the 20-day moving average (MA) of 35.10, above the 50-day MA of 36.27, and below the 200-day MA of 41.62, indicating a neutral trend. The MACD of 0.71 indicates Negative momentum. The RSI at 55.67 is Neutral, neither overbought nor oversold. The STOCH value of 54.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SMLR.

Semler Scientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VREX	66 Neutral	$355.65M	―	-7.46%	―	-3.31%	-199.23%
TCMD	60 Neutral	$237.83M	15.29	8.12%	―	5.96%	-43.83%
CLPT	59 Neutral	$318.26M	―	-76.21%	―	23.22%	9.54%
SMLR	54 Neutral	$394.99M	7.47	-24.94%	―	-25.28%	-172.20%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
SRDX	49 Neutral	$418.68M	―	-16.96%	―	-14.96%	-245.49%
SENS	48 Neutral	$358.74M	―	-161.19%	―	1.64%	16.02%

Semler Scientific Corporate Events

Semler Scientific Launches CardioVanta Subsidiary for Healthcare

On June 24, 2025, Semler Scientific announced the creation of CardioVanta, Inc., a wholly-owned subsidiary dedicated to its future healthcare business activities. This strategic move aims to enhance the company’s focus on early detection of heart-related conditions and involves seeking external investment to support its initial capital requirements, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SMLR) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.

Semler Scientific Updates Bylaws for Compliance Clarity

On June 22, 2025, Semler Scientific‘s board of directors approved the Fifth Amended and Restated Bylaws, effective immediately. This amendment was made to clarify compliance with Delaware General Corporation Law and to align with the company’s certificate of incorporation, potentially impacting corporate governance and operational clarity.

The most recent analyst rating on (SMLR) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.

Semler Scientific Appoints Joe Burnett for Bitcoin Strategy

On June 19, 2025, Semler Scientific, Inc. announced the appointment of Joe Burnett as director of Bitcoin strategy. The company also revealed its ambitious plan to acquire 10,000 Bitcoins by the end of 2025, 42,000 by the end of 2026, and 105,000 by the end of 2027, utilizing funds from equity and debt financings as well as cash flows from operations.

The most recent analyst rating on (SMLR) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.

Semler Scientific Updates Bylaws for Governance Efficiency

On June 4, 2025, Semler Scientific, Inc.’s board of directors approved and adopted its Fourth Amended and Restated Bylaws to align with the current Delaware General Corporation Law. This update reflects changes such as the removal of the requirement for a stockholder list during meetings and the elimination of restrictions on actions without meetings, potentially streamlining corporate governance processes.

The most recent analyst rating on (SMLR) stock is a Buy with a $71.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.

Semler Scientific Acquires 185 Bitcoin for $20 Million

Semler Scientific has established a dashboard on its website to disclose information about its Bitcoin holdings and related financial metrics, aiming to provide transparency and comply with regulatory obligations. Between May 23 and June 3, 2025, the company acquired 185 Bitcoin for $20 million, bringing its total holdings to 4,449 Bitcoin, valued at $472.9 million, and reported a BTC Yield of 26.7% year-to-date, reflecting its strategy to enhance shareholder value through Bitcoin investments.

The most recent analyst rating on (SMLR) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.

Semler Scientific’s Recent Bitcoin Acquisition and Stock Offering

Semler Scientific announced its recent financial activities, including an at-the-market offering program initiated on April 15, 2025, allowing the company to issue and sell up to $500 million of its common stock. By May 22, 2025, the company had raised approximately $114.8 million through this program. Additionally, between May 13 and May 22, 2025, Semler Scientific acquired 455 Bitcoin for $50 million, bringing its total Bitcoin holdings to 4,264, valued at $474.4 million as of May 22, 2025. The company reported a BTC Yield of 25.8% year-to-date, which it uses as a key performance indicator to evaluate the effectiveness of its Bitcoin acquisition strategy.

The most recent analyst rating on (SMLR) stock is a Buy with a $71.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.

Semler Scientific Appoints Natalie Brunell to Board

On May 15, 2025, Semler Scientific‘s Board of Directors appointed Ms. Natalie Brunell to fill a vacancy in Class II, effective immediately, and to serve on the Bitcoin Strategy Committee. Ms. Brunell received stock options as part of her compensation, and Semler Scientific entered into a standard indemnification agreement with her, ensuring protection against certain legal expenses.

The most recent analyst rating on (SMLR) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Semler Scientific stock, see the SMLR Stock Forecast page.